Background: The wide variation in bifurcation anatomy has generated an ongoing search for stents explicitly designed for coronary bifurcations, and to date, results have been underachieved.
Methods: The POLBOS I and POLBOS II were international, multicentre, randomized, open-label, controlled trials. Patients were randomly assigned to BiOSS Expert (in POLBOS I, biodegradable polymer eluting paclitaxel)/BiOSS LIM (in POLBOS II, biodegradable polymer eluting sirolimus) stent implantation or regular drug-eluting stent (rDES) deployment. A provisional T-stenting strategy was the default treatment option. The primary endpoint of this pooled data study was the cumulative rate of major adverse cardiovascular events (MACE) consisting of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR). Telephone follow-up was performed annually up to 72 months. (ClinicalTrials.gov Identifier: POLBOS I-NCT02192840, POLBOS II-NCT02198300).
Results: The total study population consisted of 445 patients, 222 patients in the BiOSS group and 223 patients in the rDES group. The follow-up rate was 93.7% in the BiOSS group and 91.9% in the rDES group. At 72 months, there was no significant difference between BiOSS and rDES groups regarding MACE (25.7% vs 25.1%, HR 1.06, 95% CI 0.73-1.52), cardiac death (3.1% vs 4.0%, HR 0.94, 95% CI 0.43-2.34), MI (3.6% vs 4.9%, HR 0.76, 95% CI 0.32-2.89), TLR (18.9% vs 16.1%, HR 1.17, 95% CI 0.75-1.83) and stent thrombosis rates (0.9% vs 0.5%, HR 1.21, 95CI 0.75-2.09).
Conclusions: At the 6-year follow-up, clinically significant clinical events did not differ between BiOSS stents and rDES.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/eci.13555 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results.
Biomedicines
April 2024
Department of Invasive Cardiology, Centre of Postgraduate Medical Education, 01-826 Warsaw, Poland.
This multicenter, randomized study aimed to compare the sirolimus-eluting BiOSS LIM C dedicated coronary bifurcation stent with second-generation -limus drug-eluting stents (rDESs) in the treatment of non-left main (non-LM) coronary bifurcation. The deployment of a single stent in the main vessel-main branch across a side branch was the default strategy in all patients. The primary endpoint was the rate of major cardiovascular events (cardiac death, myocardial infarction, and target lesion revascularization) at 48 months.
View Article and Find Full Text PDFAcute and long-term results of percutaneous coronary intervention of bifurcation lesions with the dedicated Bioss Lim C stent: the Italian BIfurcation Observational Spontaneous Study (IBIOSS).
Minerva Med
April 2024
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy -
Article Synopsis
- Percutaneous coronary intervention (PCI) for bifurcation lesions remains challenging, prompting a multicenter study to evaluate the Bioss Lim C device, designed specifically for such cases.
- The study involving 207 patients assessed both acute and long-term outcomes, focusing on complications like side branch occlusion and major adverse events (MACE) following implantation.
- Results showed that 13% of patients experienced complications shortly after the procedure, and after about 24 months, 11.1% faced major adverse events, including 4.8% deaths, indicating the need for careful management during and after treatment.
Clinical outcomes of a dedicated bifurcation stent system.
Cardiovasc Revasc Med
February 2024
DCB Academy, Milano, Italy; Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy. Electronic address:
Introduction: Percutaneous coronary intervention (PCI) of bifurcation lesions is technically challenging and associated with higher rates of complications such as stent thrombosis or in-stent restenosis. In this paper, we present the clinical outcomes of BiOSS LIM C (Balton, Poland), a dedicated bifurcation stent.
Methods: In this retrospective single-center study we analyzed the outcome of patients with bifurcation coronary artery disease treated with the BiOSS LIM C stent system.
Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
Cardiovasc Res
October 2022
Department of Cardiology, German Heart Centre Munich, Technical University Munich, Lazarettstr. 36, 80636 Munich, Germany.
Aims: Targeting vascular inflammation represents a novel therapeutic approach to reduce complications of atherosclerosis. Neutralizing the pro-inflammatory cytokine interleukin-1β (IL-1β) using canakinumab, a monoclonal antibody, reduces the incidence of cardiovascular events in patients after myocardial infarction (MI). The biological basis for these beneficial effects remains incompletely understood.
View Article and Find Full Text PDF6-year results of BiOSS stents in coronary bifurcation treatment.
Eur J Clin Invest
August 2021
Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Background: The wide variation in bifurcation anatomy has generated an ongoing search for stents explicitly designed for coronary bifurcations, and to date, results have been underachieved.
Methods: The POLBOS I and POLBOS II were international, multicentre, randomized, open-label, controlled trials. Patients were randomly assigned to BiOSS Expert (in POLBOS I, biodegradable polymer eluting paclitaxel)/BiOSS LIM (in POLBOS II, biodegradable polymer eluting sirolimus) stent implantation or regular drug-eluting stent (rDES) deployment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!